Logo
Logo

About Sitagliptin Phosphate (Anhydrous) API

Product
  • Therapeutic Category抗糖尿病

  • CAS Number

    654671-77-9

  • API Technology

    合成

  • Dose Form

    口服固体制剂

  • Dr Reddy's Development Status

    可用的

  • Available Regulatory Filing

    USDMF, 巴西 DMF, 加拿大 DMF, 韩国 DMF

Mechanism of Action


Sitagliptin works to competitively inhibit the enzyme dipeptidyl peptidase 4 (DPP-4). This enzyme breaks down the incretinsGLP-1 and GIP, gastrointestinal hormones released in response to a meal. By preventing GLP-1 and GIP inactivation, they are able to increase the secretion of insulin and suppress the release of glucagon by the alpha cells of the pancreas. This drives blood glucose levels towards normal. As the blood glucose level approaches normal, the amounts of insulin released and glucagon suppressed diminishes, thus tending to prevent an "overshoot" and subsequent low blood sugar (hypoglycemia) which is seen with some other oral hypoglycemic agents.


Indication


JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Related APIs

盐酸西格列汀

抗糖尿病

arrow

利拉鲁肽

抗糖尿病

arrow

达格列净(无定型)

抗糖尿病

arrow

利格列汀

抗糖尿病

arrow

格列美脲

抗糖尿病

arrow

盐酸吡格列酮

抗糖尿病

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone

免责声明

本網站上的任何信息,包括對任何產品或服務的任何提及,均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是,在某些情況下,雷迪博士可自行決定並根據當地法律要求,在存在此類監管豁免的任何地方,提供此類產品的研究數量,以根據《印度專利法》第 107A 條(Bolar 豁免)進行監管提交。購買者應對其各自市場的產品或服務(包括專利情況)進行獨立評估,並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證,包括但不限於適銷性、適用於特定用途和非侵權的保證。

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.